Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

Over the past decade, immunotherapy has revolutionized cancer treatment, improving the chance for cure and survival even for poor-prognosis tumors. Immune ...

The neonatal Fc receptor (FcRn) is a developmentally regulated ... and adaptive immune activities associated with professional antigen-presenting cells; such regulation is involved in protection ...

UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy Chimeric antigen receptor T-cell (CAR-T) therapies are standard of care for the treatment of several ...

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

The "Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights ...